SLC5A1 and heart failure: Unlike Dapagliflozin and Empagliflozin (selective SGLT2 inhibitors), Sotagliflozin inhibits both SGLT1 and SGLT2: SGLT1 inhibition reduces intestinal glucose absorption, and combined with SGLT2-mediated urinary glucose excretion, this dual action rapidly alleviates heart failure hemodynamic burden—driven mainly by rapid osmotic diuresis and reduced intestinal sodium absorption to lower cardiac preload.